Cargando…

Specific antibodies against vaccine-preventable infections: a mother–infant cohort study

OBJECTIVES: To determine maternal and neonatal specific antibody levels to selected vaccine-preventable infections (pertussis, Haemophilus influenzae type b (Hib), tetanus and pneumococcus). DESIGN: Prospective cohort study. SETTING: A UK secondary care maternity unit (March 2011–January 2012). PART...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Christine, Pollock, Louisa, Barnett, Sara M, Battersby, Anna, Kampmann, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641500/
https://www.ncbi.nlm.nih.gov/pubmed/23585389
http://dx.doi.org/10.1136/bmjopen-2012-002473
_version_ 1782268036633329664
author Jones, Christine
Pollock, Louisa
Barnett, Sara M
Battersby, Anna
Kampmann, Beate
author_facet Jones, Christine
Pollock, Louisa
Barnett, Sara M
Battersby, Anna
Kampmann, Beate
author_sort Jones, Christine
collection PubMed
description OBJECTIVES: To determine maternal and neonatal specific antibody levels to selected vaccine-preventable infections (pertussis, Haemophilus influenzae type b (Hib), tetanus and pneumococcus). DESIGN: Prospective cohort study. SETTING: A UK secondary care maternity unit (March 2011–January 2012). PARTICIPANTS: Mothers and infants within 72 h of delivery were eligible. Unwell individuals, mothers less than 18 years of age, and infants born at less than 36 weeks gestation, or weighing less than 2500 g, were excluded. HIV-infected mothers were included. 112 mother–infant pairs were recruited. Samples from 111 mothers and 109 infants (108 pairs) were available for analysis. OUTCOME MEASURES: Specific antibody levels were determined using standard commercial ELISAs. Specific antibody to pertussis antigens (PT and FHA) of >50 IU/ml, defined as ‘positive’ by the test manufacturer, were interpreted as protective. Antitetanus antibody titres >0.1 IU/ml and anti-Hib antibody titres >1 mg/l were regarded as protective. RESULTS: Only 17% (19/111) of women exhibited a protective antibody response against pertussis. 50% (56/111) of women had levels of antibody protective against Hib and 79% (88/111) against tetanus. There was a strong positive correlation between maternal-specific and infant-specific antibodies’ responses against pertussis (r(s)=0.71, p<0.001), Hib (r(s)=0.80, p<0.001), tetanus (r(s)=0.90, p<0.001) and pneumococcal capsular polysaccharide (r(s)=0.85, p<0.001). Only 30% (33/109) and 42% (46/109) of infants showed a protective antibody response to pertussis and Hib, respectively. Placental transfer (infant:mother ratio) of specific IgG to pertussis, Hib, pneumococcus and tetanus was significantly reduced from HIV-infected mothers to their HIV-exposed, uninfected infants (n=12 pairs) compared with HIV-uninfected mothers with HIV-unexposed infants (n=96 pairs) by 58% (<0.001), 61% (<0.001), 28% (p=0.034) and 32% (p=0.035), respectively. CONCLUSIONS: Low baseline antibody levels against pertussis in this cohort suggest the recently implemented UK maternal pertussis immunisation programme has potential to be effective.
format Online
Article
Text
id pubmed-3641500
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36415002013-05-07 Specific antibodies against vaccine-preventable infections: a mother–infant cohort study Jones, Christine Pollock, Louisa Barnett, Sara M Battersby, Anna Kampmann, Beate BMJ Open Immunology (Including Allergy) OBJECTIVES: To determine maternal and neonatal specific antibody levels to selected vaccine-preventable infections (pertussis, Haemophilus influenzae type b (Hib), tetanus and pneumococcus). DESIGN: Prospective cohort study. SETTING: A UK secondary care maternity unit (March 2011–January 2012). PARTICIPANTS: Mothers and infants within 72 h of delivery were eligible. Unwell individuals, mothers less than 18 years of age, and infants born at less than 36 weeks gestation, or weighing less than 2500 g, were excluded. HIV-infected mothers were included. 112 mother–infant pairs were recruited. Samples from 111 mothers and 109 infants (108 pairs) were available for analysis. OUTCOME MEASURES: Specific antibody levels were determined using standard commercial ELISAs. Specific antibody to pertussis antigens (PT and FHA) of >50 IU/ml, defined as ‘positive’ by the test manufacturer, were interpreted as protective. Antitetanus antibody titres >0.1 IU/ml and anti-Hib antibody titres >1 mg/l were regarded as protective. RESULTS: Only 17% (19/111) of women exhibited a protective antibody response against pertussis. 50% (56/111) of women had levels of antibody protective against Hib and 79% (88/111) against tetanus. There was a strong positive correlation between maternal-specific and infant-specific antibodies’ responses against pertussis (r(s)=0.71, p<0.001), Hib (r(s)=0.80, p<0.001), tetanus (r(s)=0.90, p<0.001) and pneumococcal capsular polysaccharide (r(s)=0.85, p<0.001). Only 30% (33/109) and 42% (46/109) of infants showed a protective antibody response to pertussis and Hib, respectively. Placental transfer (infant:mother ratio) of specific IgG to pertussis, Hib, pneumococcus and tetanus was significantly reduced from HIV-infected mothers to their HIV-exposed, uninfected infants (n=12 pairs) compared with HIV-uninfected mothers with HIV-unexposed infants (n=96 pairs) by 58% (<0.001), 61% (<0.001), 28% (p=0.034) and 32% (p=0.035), respectively. CONCLUSIONS: Low baseline antibody levels against pertussis in this cohort suggest the recently implemented UK maternal pertussis immunisation programme has potential to be effective. BMJ Publishing Group 2013-04-11 /pmc/articles/PMC3641500/ /pubmed/23585389 http://dx.doi.org/10.1136/bmjopen-2012-002473 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode
spellingShingle Immunology (Including Allergy)
Jones, Christine
Pollock, Louisa
Barnett, Sara M
Battersby, Anna
Kampmann, Beate
Specific antibodies against vaccine-preventable infections: a mother–infant cohort study
title Specific antibodies against vaccine-preventable infections: a mother–infant cohort study
title_full Specific antibodies against vaccine-preventable infections: a mother–infant cohort study
title_fullStr Specific antibodies against vaccine-preventable infections: a mother–infant cohort study
title_full_unstemmed Specific antibodies against vaccine-preventable infections: a mother–infant cohort study
title_short Specific antibodies against vaccine-preventable infections: a mother–infant cohort study
title_sort specific antibodies against vaccine-preventable infections: a mother–infant cohort study
topic Immunology (Including Allergy)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641500/
https://www.ncbi.nlm.nih.gov/pubmed/23585389
http://dx.doi.org/10.1136/bmjopen-2012-002473
work_keys_str_mv AT joneschristine specificantibodiesagainstvaccinepreventableinfectionsamotherinfantcohortstudy
AT pollocklouisa specificantibodiesagainstvaccinepreventableinfectionsamotherinfantcohortstudy
AT barnettsaram specificantibodiesagainstvaccinepreventableinfectionsamotherinfantcohortstudy
AT battersbyanna specificantibodiesagainstvaccinepreventableinfectionsamotherinfantcohortstudy
AT kampmannbeate specificantibodiesagainstvaccinepreventableinfectionsamotherinfantcohortstudy